News | Atrial Fibrillation | September 24, 2015

ACC Launches Two Afib-Related Registry Programs

Registries to track ablation and left atrial appendage occlusion procedures

ACC, atrial fibrillation registries, ablation, left atrial appendage occlusion procedures, LAAO Registry

September 24, 2015 — The American College of Cardiology (ACC) launched two new clinical registry programs in August to track real-world outcomes for the treatment and stroke prevention of patients with atrial fibrillation.

“With a growing prevalence of atrial fibrillation and growing options for treatment and stroke prevention in afib patients, the ACC saw a need for real-world data to track and evaluate the use of these new technologies,” said ACC President Kim A. Williams Sr., M.D., FACC. “Data derived from these registries are expected to inform practices and improve patient outcomes.”

In coming months, the ACC will launch the LAAO Registry, which will capture data on left atrial appendage occlusion procedures to assess real-world procedural indications and outcomes, as well as short- and long-term safety. Left atrial appendage occlusion procedures provide a treatment option to manage stroke risk for non-valvular atrial fibrillation patients who are unable to maintain adequate anticoagulation through medication therapy.

The college is also planning the AFib Ablation Registry to assess the prevalence, demographics, acute management and outcomes of patients undergoing atrial fibrillation ablation procedures. Its data will support the development of evidence-based guidelines and quality metrics for atrial fibrillation treatments that will improve outcomes for afib patients.

These two new clinical registry programs join eight other programs that comprise the National Cardiovascular Data Registry, the ACC’s suite of cardiovascular data registries that help hospitals and clinical practices measure and improve the quality of care they provide. 

For more information: www.acc.org


Related Content

News | Atrial Fibrillation

April 18, 2024 — New evidence-based research calls into question the conventional three-month blanking period ...

Home April 18, 2024
Home
News | Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 28, 2024
Home
News | Atrial Fibrillation

February 27, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home February 27, 2024
Home
News | Atrial Fibrillation

February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in ...

Home February 06, 2024
Home
News | Atrial Fibrillation

February 2, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home February 02, 2024
Home
News | Atrial Fibrillation

January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed ...

Home January 18, 2024
Home
News | Atrial Fibrillation

December 29, 2023 — Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety ...

Home December 29, 2023
Home
News | Atrial Fibrillation

December 26, 2023 — Pulse Biosciences, Inc., a company primarily focused on leveraging its novel and proprietary CellFX ...

Home December 26, 2023
Home
News | Atrial Fibrillation

December 22, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home December 22, 2023
Home
News | Atrial Fibrillation

December 14, 2023 — Medtronic plc, a global leader in healthcare technology, today announced that the United States Food ...

Home December 14, 2023
Home
Subscribe Now